Quantcast

Anemia – Pipeline Assessment and Market Forecasts to 2017 Now Available Sandler Research

November 1, 2010

DALLAS, November 1, 2010 /PRNewswire/ — Sandler Research announces it
will carry Anemia – Pipeline Assessment and Market Forecasts to 2017 Research
Report in its store.

Browse the complete Report on:
http://www.sandlerresearch.org/reports/37162-anemia-pipeline-assessment-and-m
arket-forecasts-to-2017.html

    Browse All Food and Beverages Reports:

http://www.sandlerresearch.org/market-research/pharmaceuticals/

Search More Then 20000 Market Research Reports at
http://www.sandlerresearch.org/

    Browse All GlobalData Research Reports at

http://www.sandlerresearch.org/publishers/globaldata/

GlobalData, the industry analysis specialist, has released its new
report, “Anemia – Pipeline Assessment and Market Forecasts to 2017″. The
report is an essential source of information and analysis on the global
Anemia market. The report identifies the key trends shaping and driving the
global Anemia market. The report also provides insights on the prevalent
competitive landscape and the emerging players expected to significantly
alter the market positioning of the current market leaders. Most importantly,
the report provides valuable insights on the pipeline products within the
global Anemia sector.

This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by
GlobalData’s team of industry experts.

GlobalData valued the anemia market in 2009 at $10.4 billion, indicating
a CAGR of 7.4% between 2001 and 2009. The main driver for the growth of the
anemia market is the rapid utilization of Erythropoietin Stimulating Agents
(ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen
(epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological
in nature and the annual cost of anemia therapy with these drugs ranges
between $3,000 and $8,000. The majority of these therapies were launched
between 2001 and 2007 and as a result market growth was pronounced in that
period. In 2007, safety concerns over the use of ESAs surfaced and this has
led to a decline in sales of the drugs. Since then, growth in the anemia
market has been declining. Between 2009 and 2017, the market is expected to
decline further as there are no key promising therapies expected to enter the
anemia market. Furthermore, biosimilars of ESAs have already entered the
European market and are expected to enter the US market between 2009 and
2017. This factor is also expected to restrain the growth of the market.

Scope

The report provides information on the key drivers and challenges of the
Anemia market. Its scope includes:

    - Annualized global Anemia market revenues data from 2001 to
    2009, forecast for eight years to 2017.
    - Pipeline analysis data providing a split across the different
    phases, mechanisms of action being developed and emerging trends.
    Pipeline candidates fall under major therapeutic classes such as
    Erythropoesis Stimulating Agent, Oral HIF-PH inhibitor, TGF- beta
    inhibitors, Fetal globin gene expression stimulator, oral EPO inducers,
    EPO mimetic peptide.
    - Analysis of the current and future competition in the global
    Anemia market. Key market players covered are Amgen Inc, Roche, Jhonson
    & Jhonson, Vifor Inc, and Affymax.
    - Insightful review of the key industry drivers, restraints and
    challenges. Each trend is independently researched to provide a
    qualitative analysis of its implications.
    - Key topics covered include strategic competitor assessment,
    market characterization, unmet needs and the implications for the Anemia
    therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow
you to:

    - Develop and design your in-licensing and out-licensing
    strategies through a review of pipeline products and technologies and by
    identifying the companies with the most robust pipeline.
    - Develop business strategies by understanding the trends shaping
    and driving the global Anemia market.
    - Drive revenues by understanding the key trends, innovative
    products and technologies, market segments and companies likely to impact
    the global Anemia market in future.
    - Formulate effective sales and marketing strategies by
    understanding the competitive landscape and by analyzing the performance
    of various competitors.
    - Identify emerging players with potentially strong product
    portfolios and create effective counter-strategies to gain a competitive
    advantage.
    - Organize your sales and marketing efforts by identifying the
    market categories and segments that present maximum opportunities for
    consolidations, investments and strategic partnerships.
    - What's the next big thing in the global Anemia market landscape?
    - Identify, understand and capitalize

    Browse All Latest Reports:

http://www.sandlerresearch.org/LatestReport.aspx

Related Reports

Influenza Vaccines – Pipeline Assessment and Market Forecasts to 2017
(http://www.sandlerresearch.org/reports/36584-influenza-vaccines-pipeline
-assessment-and-market-forecasts-to-.html)

Head and Neck Cancer – Pipeline Assessment and Market Forecast to 2017
(http://www.sandlerresearch.org/reports/36585-head-and-neck-cancer-pipeline
-assessment-and-market-forecast-to.html)

Rheumatoid Arthritis – Pipeline Assessment and Market Forecasts to 2017
(http://www.sandlerresearch.org/reports/37160-rheumatoid-arthritis-pipeline
-assessment-and-market-forecasts-t.html)

Systemic Lupus Erythematosus – Pipeline Assessment and Market Forecasts
to 2017 (http://www.sandlerresearch.org/reports/37161-systemic-lupus-
erythematosus-pipeline-assessment-and-market-for.html)

Peripheral Arterial Disease (PAD) – Pipeline Assessment and Market
Forecasts to 2017 (http://www.sandlerresearch.org/reports/37204-peripheral
-arterial-disease-pad-pipeline-assessment-and-marke.html)

Growth Hormone Deficiency (GHD) – Pipeline Assessment and Market
Forecasts to 2017(http://www.sandlerresearch.org/reports/37205-growth-
hormone-deficiency-ghd-pipeline-assessment-and-market-.html)

Type 1 Diabetes – Drug Pipeline Assessment and Market Forecasts to 2017
(http://www.sandlerresearch.org/reports/25702-type-1-diabetes-drug-pipeline
-assessment-and-market-forecasts-t.html)

Hormone Replacement Therapy in Menopause – Pipeline Assessment and Market
Forecasts to 2017(http://www.sandlerresearch.org/reports/27388-hormone-
replacement-therapy-in-menopause-pipeline-assessment-an.html)

Erectile Dysfunction – Pipeline Assessment and Market Forecasts to 2017
(http://www.sandlerresearch.org/reports/32787-erectile-dysfunction-pipeline-
assessment-and-market-forecasts-t.html)

Type 2 Diabetes – Pipeline Assessment and Market Forecasts to 2017
(http://www.sandlerresearch.org/reports/32788-type-2-diabetes-pipeline
-assessment-and-market-forecasts-to-201.html)

(Due to the length of these URLs, it may be necessary to copy and paste
the hyperlink into your Internet browser’s URL address field. Remove the
space if one exists.)

About Us

Sandler Research comprises an online library of 20,000 reports, in-depth
market research studies of over 5000 micro markets, and 25 industry specific
websites. Our client list boasts almost all well-known publishers of such
reports across the globe. We as a third-party reseller of market research
reports employ a number of marketing tools, such as press releases,
email-marketing and effective search-engine optimization techniques to drive
revenues for our clients. We also provide 24/7 online and offline support
service to our customers.

    Contact:

    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004

http://www.sandlerresearch.org/

SOURCE MarketsandMarkets


Source: newswire



comments powered by Disqus